A61P 9 - Drugs for disorders of the cardiovascular system

Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
12/2004
12/02/2004	US20040242866 Tricyclic benzodiazepines as vasopressin receptor antagonists
12/02/2004	US20040242853 Glp-1 exendin-4 peptide analogs and uses thereof
12/02/2004	US20040242851 Immunoglobulin specifiic for vascular endothelial growth factor receptor for use in treatment and prevention of tumor; angiogenesis inhibitors; antitumor agents; antimetastasis agents; immunotherapy
12/02/2004	US20040242842 Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use
12/02/2004	US20040242694 Remedial agent for cardiac failure
12/02/2004	US20040242692 4-(3-(2,6-Dimethoxybenzyloxy)phenyl)-4-oxobutyric acid or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis
12/02/2004	US20040242687 Thrombus/thrombogenesis inhibitors
12/02/2004	US20040242683 Orally administering to the patient a therapeutically effective amount of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate in a pharmaceutical composition with food; use in treatment of cardiovascular disease, coronary heart disease, coronary artery disease
12/02/2004	US20040242682 Compositions comprising arginine and nitrates
12/02/2004	US20040242678 Apolipo protein e secretion promoters
12/02/2004	US20040242672 Pyrrolidine derivatives
12/02/2004	US20040242660 Combinations of oxazolidinones with other active ingredients for the prophylaxis and/or treatment of thromboembolic disorders
12/02/2004	US20040242659 Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
12/02/2004	US20040242657 Reaction of a phenoxypropionic acid compound with a trifluoromethylphenylthiazole compound; for manufacture of a medicament for treatment of a human peroxisome proliferator activated receptor alpha mediated disease or condition such as hypercholesteremia, cardiovascular disease
12/02/2004	US20040242656 N-heterocyclicamide compounds; useful in the treatment of cardiovascular disorders, in particular, as an anticoagulant
12/02/2004	US20040242651 to gastrointestal systems, kidneys
12/02/2004	US20040242648 Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity
12/02/2004	US20040242647 Use of organic compounds
12/02/2004	US20040242637 drugs used for signal transduction modulation, and for prophylaxis of angiogenesis, cancers, tumors, atherosclerosis, vision disorders and inflammatory diseases in mammals
12/02/2004	US20040242636 Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity
12/02/2004	US20040242629 Quinuclidine carbamate derivatives and their use as M3 antagonists
12/02/2004	US20040242627 2-Iminoimidazole derivatives (1)
12/02/2004	US20040242598 Phosphodiesterase 4 inhibitors
12/02/2004	US20040242595 Pyrimidine derivatives
12/02/2004	US20040242592 2-Substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors
12/02/2004	US20040242578 Pyrimidineamines as angiogenesis modulators
12/02/2004	US20040242575 for use with various disorders including sleep disorders; depression; cardiovascular disorders; pain; neurodegenerative disorders; psychiatric disorders etc.
12/02/2004	US20040242574 Anticancer agents; antiarthritic agents
12/02/2004	US20040242567 alone or in combination with a diuretic agent; diabetic nephropathy
12/02/2004	US20040242565 Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy
12/02/2004	US20040242564 1,2,3,4-tetrahydroisoquinolines derivatives
12/02/2004	US20040242545 Remedy for glaucoma comprising as the active ingredient compound having p13 kinase inhibitory effect
12/02/2004	US20040242536 controlled-release mixtures of plant extracts, gelation polymers and drugs such as ximelagatran, used for prophylaxis of cardiovascular disorders
12/02/2004	US20040242516 Antisense modulation of apolipoprotein(a) expression
12/02/2004	US20040242515 Trp1, mct, or ftz-f1 homologous proteins involved in the regulation of energy home-ostasis
12/02/2004	US20040242491 For use in the treatment of gout and related symptoms or in the amelioration of symptoms related to a high level of uric acid such as muscle spasm, localized swelling, inflammation, joint pains, muscle fatigue, or as a dietary supplement
12/02/2004	US20040242479 Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival of cells
12/02/2004	US20040242474 High density lipoprotein-reactive peptides
12/02/2004	US20040242455 which exerts potent and selective activated blood coagulation factor X inhibitory activity and is useful for prevention or treatment of disease associated therewith
12/02/2004	US20040241844 Oligonucleotides for controlling expression of c-reactive protein for use in treatment of infection, autoimmune, diabetic or inflammatory disease
12/02/2004	US20040241805 Cell surface binding protein for use in treatment, diagnosis and prevention of cancer, inflammation, autoimmunity, allergy, asthma and nervous system disorders
12/02/2004	US20040241803 25 human secreted proteins
12/02/2004	US20040241800 Vascular endothelial growth factor dimers
12/02/2004	US20040241249 Prepared by ketone extraction of krill; evaporating ketone in liquid product; 2nd extraction of the solids in the product with an alcohol or acetate solvent to form a soluble lipid fraction; separating liquids and solids in 2nd product and evaporating solvent from liquid fraction; recovering solids
12/02/2004	US20040241166 Use of inhibitors of ikk-beta and method for discovery of said inhibitors
12/02/2004	US20040238781 Using genistein; preadministering before exposure to radiation; prevent tissue damage
12/02/2004	CA2526637A1 Carboxylic acid compound and medecine comprising the same
12/02/2004	CA2526493A1 Means for preventing and treating cellular death and their biological applications
12/02/2004	CA2526374A1 2-aminoquinoline derivatives
12/02/2004	CA2526027A1 Process for making spirolactone compounds
12/02/2004	CA2525946A1 Composition comprising a pde4 inhibitor and a pde5 inhibitor
12/02/2004	CA2525501A1 Tetrahydroisoquinoline derivatives as ppar-.alpha. activators
12/02/2004	CA2489124A1 Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
12/02/2004	CA2469528A1 Peptide and peptide mimetic derivatives having integrin inhibitor properties iii
12/01/2004	EP1482041A1 Nnl6 tie receptor tyrosine kinase ligand homologues
12/01/2004	EP1482040A2 NL3 TIE receptor tyrosine kinase ligand homologues
12/01/2004	EP1481976A1 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
12/01/2004	EP1481969A1 Piperidine derivative compounds and drugs containing the compounds as the active ingredient
12/01/2004	EP1481675A1 Body temperature elevating agents
12/01/2004	EP1481670A1 Medicinal composition for diagnosis, prevention, or therapy of multiple risk factor syndrome
12/01/2004	EP1481667A1 NEP inhibitors for the treatment of female sexual dysfunction
12/01/2004	EP1481250A2 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents
12/01/2004	EP1481077A2 Mitotic kinesin inhibitors
12/01/2004	EP1481067A1 Expression cassette for persistence of expression of a gene of interest in muscle cells
12/01/2004	EP1481066A2 Single nucleotide polymorphisms predicting adverse drug reactions and medication efficacy
12/01/2004	EP1481065A2 Method for detection of leptin receptor ligands
12/01/2004	EP1480999A2 (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
12/01/2004	EP1480993A2 Desaturase genes, enzymes encoded thereby, and uses thereof
12/01/2004	EP1480986A1 Novel benzothiazine and benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same
12/01/2004	EP1480983A1 Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropydimido[1,2-a]pyrimidin-4-one derivatives
12/01/2004	EP1480981A1 1-(alkyl), 1-(heteroaryl)alkyl and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1h)-one derivatives
12/01/2004	EP1480980A2 Syntheses of quinazolinones
12/01/2004	EP1480976A1 Thiazole derivatives as npy receptor antagonists
12/01/2004	EP1480973A1 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
12/01/2004	EP1480972A2 Compounds possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders
12/01/2004	EP1480971A1 Isoquinoline derivatives
12/01/2004	EP1480966A1 Compounds and methods of treating cell proliferative diseases
12/01/2004	EP1480964A1 Inhibiteurs de l'angiogenese
12/01/2004	EP1480962A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
12/01/2004	EP1480959A1 Piperazine derivatives as anti-inflammatory agents
12/01/2004	EP1480957A1 Hppars activators
12/01/2004	EP1480948A1 Semicarbazide derivatives and their use as antithrombotics
12/01/2004	EP1480736A2 Microcapsules having high carotenoid content
12/01/2004	EP1480688A1 N-(5- 4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine coated stents
12/01/2004	EP1480678A2 Treatment of ophthalmic disorders using urea and urea derivatives
12/01/2004	EP1480674A1 Treatment of central nervous system damage
12/01/2004	EP1480670A2 Cg3842 homologous proteins involved in the regulation of energy homeostasis
12/01/2004	EP1480669A1 Use of the insulin-like-growth factor i splice variant mgf for the prevention of myocardial damage
12/01/2004	EP1480658A2 Methods of treating vascular disease
12/01/2004	EP1480649A2 Stable pharmaceutical compositions
12/01/2004	EP1480647A1 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine d1 receptor agonists
12/01/2004	EP1480646A1 Anti-infective agents and/or immunomodulators used for preventive therapy following an acute cerebrovascular accident
12/01/2004	EP1480642A1 Peroxisome proliferator activated receptor modulators
12/01/2004	EP1480641A1 Substituted thiazoles and oxazoles that modulate ppar activity
12/01/2004	EP1480640A1 Peroxisome proliferator activated receptor modulators
12/01/2004	EP1480628A1 Use of sodium/hydrogen exchange inhibitors for the treatment of thrombotic and inflammatory diseases
12/01/2004	EP1480627A1 Methods of reducing angiogenesis
12/01/2004	EP1480621A1 Ph-sensitive cationic lipids, and liposomes and nanocapsules containing the same
12/01/2004	EP1412340A4 Process for the preparation of citalopram hydrobromide
12/01/2004	EP1318996B1 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists

1 ... 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 ... 1595